Why Amgen Is Buying Onyx for $10.4B

Why Amgen Is Buying Onyx for $10.4B Play

Aug. 26 (Bloomberg) -- Amgen agreed to buy Onyx Pharmaceuticals in a $10.4 billion transaction that gives Amgen access to a rapidly expanding cancer-drug market with a new product that offers sure revenue. Olivia Sterns reports on Bloomberg Television's "Market Makers." (Source: Bloomberg)

blog comments powered by Disqus